ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

Provided By GlobeNewswire

Last update: Apr 25, 2024

WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2024 financial results and provided a corporate update.